05-01-12 Applications of the Immune Response Principals of immunization Vaccines Immunizations
-
Upload
kelly-frye -
Category
Documents
-
view
30 -
download
2
description
Transcript of 05-01-12 Applications of the Immune Response Principals of immunization Vaccines Immunizations
17-1
05-01-12 Applications of the Immune Response
Principals of immunization
Vaccines
Immunizations
Monoclonal antibodies
Immunological tests
17-2
Principals of immunization
• Active immunity – immune response in an individual
upon exposure to antigen; naturally from active
infection or artificially via vaccination
• Passive immunity – occurs during pregnancy (natural) and when Abs are supplied from another individual or animal (artificial)
17-4
Antitoxin – antibody preparation against a specific toxin
Antiserum – a preparation of serum containing protective antibodies
Immune serum globulin – passive immune preparation containing IgG (gamma globulin)
pooled blood serum from many donorsvariety of Absgiven to travelers and immunosuppressed individuals
Hyperimmune globulin – sera from donors with high levels of specific Abs
eg anti tetanus, rabies, hepatitis A and hepatitis Bgiven during disease incubation period to prevent
disease development
Herd immunity – inability of a pathogen to spread; no hosts
17-5
Vaccination History:
The first known vaccination procedures were performed by the Chinese during the Sung dynasty (A.D. 960-1280) against smallpox.
“Variolation” used small amounts of powdered crusts from smallpox pustules which were inhaled or placed in small cuts in the skin.
A mild disease was usually produced, followed by immunity to smallpox.
Variolation was practiced in Europe, but was expensive and sometimes disease resulted (1 in 100 died), so many people were not treated.
Edward Jenner, in 1796, deliberately introduced material from a cowpox lesion on a milkmaid to a scratch on the arm of a young boy (our word dairy comes from “dey-ery” the room in which the “dey”, or woman servant, made milk into butter).
Jenner subsequently exposed the boy to the pus of a smallpox victim;the boy did not develop smallpox.
Pasteur coined the word “vaccination” to describe any type of protective inoculation.
17-6
Figure 12-6
Increase in measles in the UK compared with uptake of MMR vaccine (P14.6)(MMR = Measles, Mumps, Rubella)
17-7
New York Times on Measles
http://www.nytimes.com/packages/khtml/2006/04/28/health/20060430_BRINK_AUDIOSS.html
17-8
Vaccines
• Toxoids – inactivated toxins• Protein subunit vaccines (and recombinant vaccines)
contain key protein antigensreduced unwanted side effects
• Polysaccharide vaccines – T-independent antigensconjugate vaccine – polysaccharide plus protein =
T-dependent vaccine – protection for childrenagainst H. influenza type b (meningitis) and S. pneumoniae (variety of infections)
• Adjuvant – enhances immune response to antigens, provide “danger signals”
17-9
Vaccines (cont.)
• Attenuated - weakened form of the disease-causing agentAgent replicates, may cause mild diseaseMimics wild type strain, controls infectionLonger antigen exposure than inactivated vaccinesCan cause disease in immunocompromised peopleeg Sabin polio vaccine
• Inactivated - unable to replicate; retains immunogenicitycannot cause infections or revert to dangerous formno amplification of dose in vivo; boosters requiredInactivated whole agent vaccines – killed microorganismseg Salk vaccine is a mixture of inactivated forms
of the three types of poliovirus
17-10
Viral vaccines are made from whole viruses orviral components
“Varioloation” – dried pustules from people with milder forms of small pox administered intranasally orintradermally – sometimes caused disease and death
Cowpox virus (“vaccinia”) was used by Jenner to produce immunity to smallpox; eradicated smallpox
Killed or inactivated vaccines are used for immunity againstviruses for which no natural safe counterpart exists
Subunit vaccines contain only antigenic viral surface proteins
Viral vaccine development is hampered by evasion of the host immune system (HIV), multiple genetic strains (flu)and weak immune responses (common cold)
17-12
Figure 12-2 part 1 of 2
Attenuated viruses are selected by growinghuman viruses in non-human cells (P14.2)
17-13
Figure 12-2 part 2 of 2
Attenuated viruses are selected by growinghuman viruses in non-human cells (P14.2)
17-14
Bacterial vaccines are made from whole bacteria,capsular polysaccharides or secreted toxinsToxoid – purified toxin inactivated with formalin, effective
against diphtheria and tetanusDTP combination vaccine active against diphtheria, tetanus
and pertussis (whooping cough)Pertussis bacteria act as adjuvantDTP replaced by DTaP (acellular pertussis)
Polysaccharide vaccines for encapsulated bacteria designed to elicit complement fixing Abs that bind strain-specificand pathogenicity-causing surface polysaccharides
Effective against pneumococcus, salmonellae,meningococci, H. influenzae, E. coli,Klebsiella pneumoniae, B. fragilis
T-independent antigen is converted to T-dependent antigenby coupling to carrier protein that binds T cells“conjugate vaccines”
17-15
Adjuvants nonspecifically enhance the immuneresponses
Vaccination must create a state of inflammation created bybacterial products that activate macrophages
Purified proteins do not elicit a strong immune response
The response can be enhanced by adding substances thatinduce inflammation called adjuvants (“helpers”)
Freund’s complete adjuvant is an emulsion of killed mycobacteria and mineral oil
Adjuvants cause soluble protein antigens to aggregate and precipitate to facilitate phagocytosis by APCs
17-16
Vaccination can inadvertently cause disease
Live attenuated viruses simulate actual infections and elicit the best immune stimulation
Live attenuated viruses can revert to a pathogenic form
Sabin polio vaccine induces polio and paralysis in 3people per million vaccinated
One of the three polio virus strains in Sabin vaccine differsfrom natural polio virus by only 10 nucleotidesubstitutions; can mutate to the natural strainand cause disease
17-23
Immunizations
• Paralytic poliomyelitis
• Effectiveness of immunizations
• Recommended immunizations
• Future immunizations
17-24
Paralytic poliomyelitis
• 1950 – Salk vaccine (inactivated virus)
no herd immunity – immunized people can be carriers
requires multiple injections over time
• 1960 – Sabin vaccine (attenuated virus)
• Salk vaccine is safe, but wild type virus can replicate and spread
• Sabin vaccine provides herd immunity
given orally, induces mucosal immunity
stops spread, gives herd immunity
can cause vaccine-related polio in some individuals
17-25
New York Times on polio
http://video.on.nytimes.com/index.jsp?fr_story=77549ceb1b1ae1777e43d4eedfaf7bcff47b0a31
17-26
Immunological testing
• Monoclonal antibodies
• Serology
• Quantifying antigen – antibody reactions
17-27
Therapeutic MAbs:
1895 – French physicians use antiserum from dogs to treat cancer some patients improved but had immunogenicity problems
nobody cured
2005 – 100 therapeutic MAbs in clinical trials18 MAbs approved for use in the US$5-6 billion in revenues in 2003may triple in next five yearspossibly 32% of biotech market by 2008
Genentech produces three anticancer MAbs:HerceptinAvastinRituxan$2.7 billion in revenues in 2004
17-29
Problems and solutions encountered during MAb drug development:
1. Removal of inappropriate Abs from antiserasolution: MAbs (Milstein and Kohler, 1984)produce single mouse Ab
2. Mouse MAbs were immunogenic in humanssolution: “humanization” of mouse MAbsMouse variable regions fused to human constant
regions = chimeric MAb reduced HAMA
3. Chimeric drugs Rituxin (rituximab; binds CD-20 on B cell to combat non-Hodgkin lymphoma); Remicade (infliximab) have been associated with serious allergic reactions
solution: insert mouse complementary-determining regions (CDRs) into human Ab = humanized MAbs 90-95% human fewer HAMA responses
17-30
4. Humanized MAbs technically demanding, reduced Ag affinities solution: fully human MAbs to evade human immune response
a. change the mouse: Xenomouse, HuMab-Mouse are transgenic animals with human Ab genes
11 xenomouse MAbs in clinical trialseg panitumumab – targets EGF receptor to combat metastatic colorectal cancer
150 HuMab-Mouse MAbs in developmenteg MDX-010 – anti-CTLA-4 formetastatic melanoma in clinical trials
binding of CTLA-4 blocksinhibition of T-cell proliferationeffector T cells eliminate tumors
17-31
4. Humanized MAbs technically demanding, reduced Ag affinities solution: fully human MAbs to evade human immune response
b. skip the mouse: in vitro phage display technology used to produce human MAbs
libraries of human MAbs contain more than100 billion different phage antibodies
screen to select for strong binding to specific Ag
17-34
Principles of Immunological Testing
• Terms– Seronegative
• Person not yet exposed to antigen and has no specific antibodies
– Seropositive• Person with exposure and actively producing
antibody– Titer
• Concentration of antibody in serum• Indicates previous exposure
17-35
Using Labeled Antibodies to Detect Interactions
• Detectable markers can be attached to specific antibodies– Marked antibodies used to detect presence of given antigen
• Tests include– Fluorescent Antibody (FA) test – Enzyme-Linked Immunosorbant Assay (ELISA)– Western blotting– Fluorescence Activates Cell Sorter (FACS)
17-36
Using Labeled Antibodies to Detect Interactions
• Fluorescent antibody test
– Relies on fluorescent microscopy to locate labeled antibodies fixed to a microscope slide
– Fluorescent polarized immunoassay uses beam of polarized light to rate spin of labeled antibodies
• Works under principle that bound antibodies are heavier then unbound and will spin more slowly
17-38
Using Labeled Antibodies to Detect Interactions
• Enzyme-Linked Immunosorbant Assay– Employs antibody that has been labeled with detectable
enzyme• Commonly horseradish peroxidase
– Labels antibody bonds to antigen• Binding can be direct or indirect
– Antigen location is determined using colormetric assay
17-39
• Enzyme-Linked Immunosorbant Assay
– Direct ELISA
• Looks for specific antigen
– Specimen placed in wells of microtiter plate
» Wells treated with antibody for antigen
– Indirect ELISA
• Looks for antibody in patient serum
– Human IgG
– Wells of plate treated with known antigen
Using Labeled Antibodies to Detect Interactions
17-41Direct ELISA test for pregnancy (18.12)
Detects human chorionic gonadotropinPresent only in pregnant women
17-42
Western blot for HIV (18.13)
Ags separated by electorphoresis
Transferred to membrane
Probed with specific Abs
Abs detected indirectlyusing anti-HGG
30
26
31
gp 160
gp 120
p66
p55gp41
p39
p31
p24
p17
Serumcontrol
(a) Strong reactive control(b) Weak reactive control(c) Non-reactive control
Courtesy of Genelabs Diagnostics
ca b